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Supplementary Figure 1: The efficiency of RR-seq-based mutational calling across 
the PCAWG tumor types. 
A) The distribution of cosine similarities between the RR-seq computational simulation-derived (best 
combination of enzyme per tumor type) and WGS-based mutational signatures. Data are shown as 
boxplots, where the bold line at the center indicates the median and the upper and lower hinges 
extend to the 25th and 75th percentile, respectively. The upper/lower whisker extends from the 
upper/lower hinge to the largest/smallest value no further than 1.5 times the interquartile range from 
the upper/lower hinge. Samples outside this range are indicated as points. For each cancer type the 
number of samples per group (N) is indicated within the x-axis labels. 
B) Scatterplot of the log10-scaled median number of mutations (x-axis) and the median performance 
of the RR-seq computational simulation-based mutational signatures measured by cosine similarity to 
the WGS-based mutational signatures (y-axis) per PCAWG cancer type. Each point represents one 
cancer type. 
C) Mutational signatures computationally simulated across the PCAWG cohort. Summary of the cosine 
similarities (y-axis) of WGS-derived mutational signatures and mutational signatures derived from 
subsets of mutations simulating different sequencing approaches (x-axis) for each of the of individual 
tumor types from the PCAWG cohort. Boxes show the 25% and 75% quartile with the median across 
the samples indicated by the bold line. Whiskers extend to 1.5 times the interquartile range and 
samples outside this range are indicated as points. Different enzyme combinations were simulated for 
RR-seq, each shown as a different box. RR-Seq – reduced representation sequencing, WES – whole 
exome sequencing, expanded WES – whole exome sequencing expanded to untranslated regions and 
miRNAs. Title of each page contains abbreviated tumor name (explained in Supplementary Figure 1) 
and the number of samples used for the analysis. 
Abbreviations: Eso-AdenoCa – Esophageal Adenocarcinoma; AdenoCA – Adenocarcinoma; Lymph-
BNHL – B-cell Non-Hodgkin Lymphoma; HCC – Hepatocellular Carcinoma; Head-SCC – Head and Neck 
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Squamous Cell Carcinoma; Panc-AdenoCA – Pancreatic Adenocarcinoma; CNS-Medullo – 
Medulloblastoma and variants; RCC – Renal Clear Cell adenocarcinoma, papillary type; Myeloid-AML 
– Acute Myeloid Leukaemia; Bone-Osteosarc – Osteosarcoma; Myeloid-MPN – Myeloproliferative 
neoplasm; Lymph-CLL – Chronic Lymphocytic Leukaemia; Prost-AdenoCa – Prostate Adenocarcinoma; 
Bone-Epith – Adamantinoma, Chordoma; Panc-Endocrine – Neuroendocrine carcinoma; CNS-






Supplementary Figure 2 – Summaries of the genome-wide distribution of loci 
resulting from the different sequencing approaches 
A) Bar plot of the number of genome-wide consecutive 1Mbps bins that are not covered by at least 
one expected loci in the computational simulation for each RR-seq with different enzyme 
combinations and (expanded) WES (x-axis).  
B) Summary of the number of expected loci per 1 million base pair (Mbp) bin (n=3211 genome-wide 
consecutive bins) on logarithmic scale (y-axis) for each RR-seq with different enzyme combinations 
and (expanded) WES (x-axis). Data are shown as boxplots, where the bold line at the center indicates 
the median and the upper and lower hinges extend to the 25th and 75th percentile, respectively. The 
upper/lower whisker extends from the upper/lower hinge to the largest/smallest value no further 





Supplementary Figure 3 – Optimization of mutREAD library preparation using 
FLO1 cell line 
A) Bioanalyser traces for the optimization of the single step double digestion and ligation. 500 ng of 
FLO1 genomic DNA was used for ligation of mutREAD adapters in the presence of indicated enzymes 
and underwent PCR amplification (20 cycles) using Illumina compatible primers. Samples before (-) 
and after (+) PCR are shown for each enzyme combination. Dilution indicates dilution of samples for 
bioanalyzer analysis (for samples that exceeded recommended detection range).  
B) Bioanalyser traces for different titration of ratios of AMPure beads and ligated DNA solution (50ul) 
to optimize the double size selection of the fragments in the library. 
C) Bioanalyser traces prepared under optimised PCR cycles conditions. Note significant decrease in 
the level of ApoI only fragments when compared to 20 PCR cycles (A).  
D) Bioanalyser traces showing improved bands for FFPE samples after treatment with FFPE repair mix 
and library preparation with optimized protocol. 
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All samples were run using DNA High Sensitivity Bioanalyzer kit with standard DNA ladder. Green and 
purple bands indicate lower and upper markers respectively. The experiments were repeated twice 





Supplementary Figure 4 – Comparison of the expected and sequenced fragment 
size distribution. 
A) Fragment size (x-axis) distribution of sequencing libraries measured on the Tape-station. 
Electropherograms of DNA fragments from three samples derived from FFPE (neat), Fresh Frozen (FF, 
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1:4 dilution) and matching blood samples (1:4 dilution) with the average size of libraries highlighted 
above the plot. LM – lower marker, UM – upper marker, FU – fluorescent units. 
B) Fragment size distribution derived from read-pairs mapped to the human genome. Each plot shows 
the number of fragments (y-axis) for each length in base pairs (x-axis). The fragment length was 
calculated as the number of base pairs between the 5’ ends of the read mates (including restriction 
site parts but not adapters or barcode sequences) and summarized to a histogram using Picard’s 





Supplementary Figure 5 – Comparison of the fragment size distributions for 
technical replicates of FFPE samples and blood  
Fragment size distribution derived from read-pairs mapped to the human genome. Each plot shows 
the number of fragments (y-axis) for each length in base pairs (x-axis) for the two technical replicates 
of FFPE tumor samples and the corresponding blood sample per patient. The fragment length was 
calculated as the number of base pairs between the 5’ ends of the read mates (including restriction 









A) mutREAD adapter sequences 
Adapter Adapter name Sequence 
mutREAD-i5 
mutREAD-i5-upper_1_ATGAGCGA 5'-C GCT CTT CCG ATC T HNNNATGAGCGATGCA-phos-3' 








   
B) mutREAD primer sequences 







   
Legend   
NNNNN Unique Molecular Identifier  
NNNNN Inner sample barcode  
NNNNN Outer sample barcode  
25 
 
Supplementary Table 1 – mutREAD adapters and primers 
A) Summary of the sequences of mutREAD adapters used for ligation to DNA fragments. Color of the nucleotides indicates specific elements of the adapters 
(unique molecular identifiers, inner samples barcodes). Ambiguous base codes H and D translate to bases A/C/T and A/G/T, respectively. Adapter names 
include the arm of the adapter (i5 contains PstI compatible end and i7 – ApoI compatible end) and the sequence of the samples barcode. 
B) Summary of the Illumina compatible primers used for amplification of the ligated libraries. Color indicates the sequences and location of outer sample 
barcode. Adapter names include the arm of the primer (i5XX is compatible with i5 adapter and i7XX with i7 adapter) and the sequence of the samples barcode. 





















due to low 
quality (6) 
Percent of 













FF 158,178,068 94.54 0.09 0.37 3.83 1.17 260 
FFPE 184,526,290 93.41 0.33 0.36 4.46 1.43 215 
Blood 155,543,840 94.14 0.07 0.42 3.52 1.85 276 
Tumor2 
FF 206,790,834 92.68 0.23 0.62 5.55 0.91 263 
FFPE 43,949,748 94.92 0.23 0.47 3.41 0.98 183 
Blood 230,847,264 96.21 0.13 0.48 2.37 0.80 257 
Tumor3 
FF 231,185,296 95.00 0.07 0.46 3.56 0.92 297 
FFPE 86,259,612 94.26 0.67 0.59 3.33 1.15 178 












10x loci (11) 







at least 50x 
(13) 
Base pairs 
covered with at 










FF 175,049,803 96.54 166,936,824 98,935,164 60,297,417 1,050 
28,732 
FFPE 170,810,606 96.91 143,331,473 122,274,170 86,782,166 383 
Blood 186,266,055 96.26 - 103,044,362 60,323,363 - - 
Tumor2 
FF 195,958,931 96.63 187,858,494 147,765,532 105,375,328 1,471 
27,764 
FFPE 95,105,098 93.98 88,953,041 32,115,195 10,201,299 47 
Blood 193,634,665 96.61 - 147,906,131 111,689,924 - - 
Tumor3 
FF 198,984,001 96.57 170,614,310 146,079,968 106,880,654 530 
11,068 
FFPE 131,586,722 95.11 113,854,654 77,474,870 36,663,830 90 




Supplementary Table 2 – Quality metrics for mutREAD libraries derived from tumor, FFPE and blood samples of three patients.  
The table summarizes quality metrics for each sample, including fresh-frozen (FF) and formalin-fixed paraffin-embedded (FFPE) tumor, as well as blood 
samples (column 2) from three patients (column 1). Sample groups of three were sequenced on one lane, where each sample had a unique outer barcode. 
Number of reads derived from the libraries de-multiplexed by outer barcode are listed in column 3. Percentages (with respect to column 3) of reads that are 
retained for further analysis (column 4) or filtered due to an unidentifiable inner barcode (column 5), low read quality (column 6), wrong/unexpected inner 
barcode (column 7), missing restriction site overhang (column 8) are listed in the respective columns. The average fragment size derived from read pair mates 
after mapping is given in column 9 (related to Supplementary Figure 4). The number of base pairs covered with at least 10x, 50x and 100x is listed in column 
10, 13 and 14, respectively. The percentage of retained reads (column 4) contributing to loci defined in column 10 is given in column 11. Finally, the overlap 
between tumor and blood samples in loci defined in column 10 is shown in column 12. The number of mutations used for deriving the mutational signatures 
is given in column 15 and 16. 
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A) Number mutations (fresh-frozen)    
  
mutREAD WGS 
Mutect2 Strelka Consensus Mutect2 Strelka Overlap 
Tumor1 1050 520 440 28732 27370 26048 
Tumor2 1471 839 714 27764 26540 25284 
Tumor3 530 339 217 11068 10398 9950 
       
B) Cosine similarity with WGS (fresh-frozen)   
  Mutect2 Strelka Consensus    
Tumor1 0.96 0.94 0.92    
Tumor2 0.95 1.00 0.99    
Tumor3 0.96 0.84 0.83    
       
C) Number mutations 
(FFPE)     
  Mutect2 Strelka Consensus    
Tumor1 383 811 104    
Tumor2 47 420 27    
Tumor3 90 838 45    
       
D) Cosine similarity with WGS (FFPE)    
  Mutect2 Strelka Consensus    
Tumor1 0.89 0.83 0.76    
Tumor2 0.93 0.81 0.89    
Tumor3 0.96 0.81 0.88    
 
Supplementary Table 3 – Comparison of Mutect2 and Strelka mutation calling 
pipelines 
The tables A and C summarize the number of mutations detected by Mutect2 and Strelka, as well as 
the overlap/consensus between the two mutation callers, for the three fresh-frozen (mutREAD and 
WGS) and FFPE tumor samples, respectively. The cosine similarity of mutREAD-derived and WGS-
derived mutational signatures is summarized in tables B and D for the fresh-frozen and FFPE samples, 
respectively. For each mutation caller and the consensus set, the mutational signatures were 
calculated from respective mutREAD-derived and WGS-derived mutation set and compared against 
each other using cosine similarity. 
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demultiplexing Properly paired reads 
Base pairs covered 
with at least 10x 
Percent of retained 
reads contributing 
to 10x loci 
Base pairs in 10x 




Tumor1 FF 215,680,416 206,317,606 2,432,340,493 90.21 99,329,518 42 
  Blood 180,158,855 175,855,924 2,248,030,642 88.49 - - 
Tumor2 FF 329,742,782 321,605,192 2,646,459,519 88.55 77,553,550 21 
  Blood 217,304,771 210,403,566 2,444,354,485 88.51 - - 
Tumor3 FF 139,225,587 134,967,944 1,914,933,524 89.19 94,152,562 83 
  Blood 233,793,837 228,289,614 2,478,664,018 88.27 - - 
        








& PCR clone 
removal Properly paired reads 
Base pairs covered 
with at least 10x 
Percent of retained 
reads contributing 
to 10x loci 
Base pairs in 10x 




Tumor1 FF 149,007,546 146,883,752 228,030,295 92.41 396,961,129 325 
  Blood 72,706,935 69,490,692 165,989,267 89.08 - - 
Tumor2 FF 44,956,340 44,224,012 119,724,582 94.68 902,341,754 142 
  Blood 64,528,333 63,067,844 145,330,607 92.69 - - 
Tumor3 FF 74,142,650 72,864,976 156,263,110 82.16 251,229,586 46 
  Blood 84,750,728 79,661,310 187,169,707 92.76 - - 
 
 
         













filtering Properly paired reads 
Base pairs covered 
with at least 10x 
Percent of retained 
reads contributing 
to 10x loci 
Base pairs in 10x 




Tumor1 FF 150,115,473 142,432,706 175,049,803 96.54 166,936,824 1,050 
  Blood 145,505,593 137,261,472 186,266,055 96.26 - - 
Tumor2 FF 196,879,399 195,040,496 195,958,931 96.63 187,858,494 1,471 
  Blood 219,749,023 217,691,576 193,634,665 96.61 - - 
Tumor3 FF 216,676,031 214,418,984 198,984,001 96.57 170,614,310 530 
  Blood 185,303,214 175,401,460 190,613,393 96.49 - - 
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Supplementary Table 4 – Quality metrics for 10x sWGS, WES and mutREAD 
libraries derived from tumor and blood samples of three patients. 
The table summarizes quality metrics of the libraries generated by (A) 10x sWGS, (B) WES, and (C) 
mutREAD for tumor and blood samples (column 2) of the same three patients (column 1). Column 3 
and 4 gives the number of reads and properly paired read pairs used for mutation calling, respectively. 
The number of base pairs covered with at least 10x, the percentage of reads contributing to these loci 




A) Tumor biopsies 
Patient Pathologist 1 Pathologist 2 Pathologist 3 
Tumor1 70% 60% 45% 
Tumor2 50% 55% 30% 
Tumor3 30% 35% 15-20% 
   
 
B) Tumor resections 
Patient Pathologist 1 Pathologist 2 Pathologist 3 
Patient1 60% 60% 15% 
Patient2 60% 70% 20% 
Patient3 30% 60% 15% 
Patient4 N/A N/A N/A 
Patient5 30% 20% 10-15% 
Patient6 70% 40% 20% 
Patient7 20% 45% 20-25% 
Patient8 25% 45% 50% 
Patient9 50% 50% 20-25% 
 
Supplementary Table 5 – Tumor cellularity of FFPE samples estimated by 
pathology 
A) Estimated percent of tumor content for the three biopsy samples estimated by pathologist review 
of diagnostic slides.  
B) Estimated percent of tumor content for the nine tumor resection samples estimated by pathologist 





mutREAD   
No. Reagents Size Cost (£) Use per sample Per sample (£) 
1 Adapter and Primers 400ul -- 9.5ul 2 
2 T4 ligase 20,000Units 62.58 400units 1.25 
3 ApoI-HF 1000 Units 49.6 50units 2.48 
4 PstI-HF 10,000Units 41.6 50units 0.2 
5 10mM ATP 1000ul 24 4ul 0.1 
6 Ampure XP beads 5000ul 195.26 37.5ul 1.5 
7 10mM dNTPs 800ul 49.6 2ul 0.1 
8 Phusion High fidelity polymerase 100Units 61.6 1unit 0.6 
        Total: £8.23  
            
B) WES   
Sl no Reagents Size Cost (£) Per sample (£)   
1 DNA library preparation and enrichment kit 16 3,589 199   
      Total: £199    
            
C) 10x 
sWGS   
Sl no Reagents Size Cost (£) Per sample (£)   
1 Thruplex library preparation and enrichment kit 96 3,818.59 39.7   
2 Sonication 96 352 3.7   
      Total: £43    
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Supplementary Table 6 – Comparative cost evaluation for library preparation per 
sample 
A) Estimated cost of individual elements used for library preparation using the mutREAD protocol. The 
cost is estimated using reagents provided by New England Biolab, Ipswich, MA 01938 USA 
B) Cost estimate of enrichment-based whole exome sequencing provided by Agilent, Santa Clara, CA 
95051 USA. The cost does not include AMPure XP and Streptavidin beads required for the selection of 
target sequences.  
C) Cost estimate of the whole genome library preparation method provided by Takara Bio, Kusatsu, 
Shiga 525-0058, Japan. The cost does not include AMPure XP and Streptavidin beads required for the 
selection of target sequences. 
Cost of sequencing: Assuming 200x coverage for mutREAD, the per-sample cost is around £150. The 
costs for WES would be similar as both methods sample a comparable proportion of the genome. 10x 

























Supplementary Table 7 – List of restriction enzymes tested in the computational 
simulation and their restriction site sequences 
The table lists the enzymes selected as described in the Methods section and their restriction sites 
(5'→3'), with the cutting position indicated by *, highlighting the different possible overhangs. 
Ambiguous codes R and Y translate to A/G or C/T, respectively, and indicate that either base at this 
position is accepted by the enzyme.
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Tumor1 a504c27a1fd7af3a53e0b5108cc052cab5ff8d1a353800e85ea8eec766707bde 75.4 male T3 N0 
Tumor2 fa37be85256c1efbac0501eb13ae1daf9f0fcaff4a7cbb3d2f4420f70f75d334 77.1 male T3 N1 
Tumor3 da859c8e95cc5acefde4e70aaed8fc89449c2aa5d9a6cef6202041987840e0a3 75.3 male T2 N1 
Patient1 9a498e8b17034fd8bb534f0e65e12c83a73aa65908fd41f4a13f86cf35b3e0cd 80.8 female T1a Nx 
Patient2 493bf7322b8c18365466c43bf7a9e119bd4d7782147f9bc368bf4909539c43de 68.7 male T1b N0 
Patient3 078773cc36a9ab58ece5c92e50368462dea52ded70f1b0da8c66e65066a3ce53 72.4 male T3 N1 
Patient4 3180f8e34845d13e27dddd90486dba083cd87a340d919f75d29859766f7faee4 69.9 male T3 N1 
Patient5 a7376de8be895a08d2abb22b1e3ee2483fb47abc534d7c6a066b06b2f0d4459a 51.9 female T1 N0 
Patient6 75ce1bd6dbaf2d4ca50f51e6c1f2a09f3275b080539a07ac7ed962ae72c5179f 58.4 female T3 N0 
Patient7 1395dc4ab7c754e0a84c8daa3996f16e5caf11169f8a9be6c800f6da00474321 65.6 male T2 N1 
Patient8 934fe84809fc20a81f124747d5ed57817eb0f9120ea63a69a1548d514710978f 59.2 male T4a N1 
Patient9 900fdae05c90e27aba521996cc05d0a83e32dec27c271a8f14e59fa84439ed34 73.5 male T3 N0 
Supplementary Table 8 – Patients Clinical Characteristics 
The table lists the information about individual patients used in the study. Patient ID follows the convention established in figures 1 and 2. Anonymized Name 
provides ICGC patient ID that can be used to obtain the Whole Genome Sequencing data used in the study.  
 
